Stevanato Group SpA

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stevanato Group excels in 2022, eyes high value solutions growth

Stevanato Group's strong financial performance in 2022, driven by high value solutions and operational efficiency, sets a solid foundation for future growth.
Strategic focus on biologics and high growth markets, along with optimized capital spending, positions the company for long-term success.
Challenges in pricing management and capacity ramp-up require careful navigation, while opportunities in expanding high value solutions and market demand offer avenues for growth.
Overall, Stevanato Group's performance reflects resilience, strategic foresight, and a commitment to value creation, signaling a positive trajectory for the company.

Stevanato Group reports strong Q1 results, eyes biologics market growth

Stevanato Group's Q1 performance reflects robust revenue growth, profitability, and a strong order backlog, underpinned by strategic collaborations and market focus.
While facing challenges such as pricing pressures and market dynamics, the company is well-positioned to leverage opportunities in the biologics sector and innovative drug delivery solutions.
With a reiterated full-year revenue guidance and a focus on operational excellence, Stevanato Group demonstrates resilience and strategic foresight in navigating the evolving healthcare landscape.
Investors can find confidence in the company's performance, strategic strengths, and growth opportunities amidst the challenges and uncertainties in the market.

Stevanato Group SpA reports robust Q2 performance and eyes growth

Stevanato Group SpA's Q2 2023 earnings call highlighted strong performance, growth prospects, and strategic initiatives amidst market challenges.
The company's financial results, revenue breakdown, and guidance underscore its resilience and potential for sustained growth.
Addressing challenges like currency fluctuations and market dynamics while seizing growth opportunities will be key for Stevanato Group SpA's future success.

Stevanato Group reports strong Q3 earnings, eyes biologics market growth

Stevanato Group's Q3 2023 performance showcased robust revenue growth and margin expansion, despite challenges in specific segments. The company's strong presence in key biologics markets and strategic priorities for sustainable growth position it well for the future. Opportunities in expanding markets and a solid order backlog provide a positive outlook.

Stevanato Group reports 10% revenue growth in Q4 2023

Stevanato Group's 2023 performance reflects growth driven by high-value solutions and strong demand.
Despite challenges like margin pressure and supply chain issues, the company remains confident in achieving growth.
Opportunities lie in expanding capacity, enhancing product mix, and capitalizing on backlog growth.
The company anticipates a stronger second half of 2024 and foresees material revenue impact from biologic products in 2025.

Stevanato Group faces Q1 challenges, invests in growth opportunities

Stevanato Group's Q1 2024 performance was impacted by industry-wide challenges, but the company remains focused on strategic priorities and operational efficiencies.
Despite revenue decline and margin impacts, the company's commitment to growth through expansion projects and high-value solutions showcases resilience and forward-thinking.
Challenges in vial demand and customer delays are being addressed through cost management and strategic actions, while opportunities in new investments and operational focus are being pursued.
The company's leadership position, solid strategy, and emphasis on execution position Stevanato Group for long-term success despite near-term headwinds.

Stevanato Group reports modest revenue growth amidst margin challenges

Stevanato Group delivered mixed results in Q2, with revenue growth driven by the Biopharmaceutical and Diagnostic Solutions segment.
While facing margin pressures and operational challenges, the company's focus on high-value solutions and efficiency improvements bodes well for long-term prospects.
Navigating through current obstacles, Stevanato Group remains optimistic about its ability to drive growth and enhance profitability.

Stevanato Group adjusts guidance amidst challenges, eyes growth opportunities

Stevanato Group's Q3 2024 performance was impacted by challenges in Engineering and the U.S., leading to a revised full-year guidance.
Despite operational challenges, the company demonstrated strengths in capacity expansion, innovation, and revenue growth.
Addressing challenges in vial destocking and segment optimization presents opportunities for future growth and profitability.
Analyst questions highlighted the need to navigate current challenges while capitalizing on opportunities for strategic advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rating target.

Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, November 12, 2024 at 11:00 a.m. (PT). The Company will also present at.

Stevanato Group to Present at Upcoming Investor Conferences

Catalyst Pharmaceuticals

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

CPRX vs. STVN: Which Stock Is the Better Value Option?

Stevanato Group S.p.A. (NYSE:STVN ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Larry Solow - CJS Securities Patrick Donnelly - Citi Jacob Johnson - Stephens Dave Windley - Jefferies Paul Knight - KeyBanc Capital Markets Dan Leonard - UBS Curtis Moiles - BNP Paribas Exane Operator Good afternoon.

Stevanato Group S.p.A. (STVN) Q3 2024 Earnings Call Transcript

Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.16 per share a year ago.

Stevanato Group (STVN) Q3 Earnings Match Estimates

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue.

Stevanato Group Reports Financial Results for the Third Quarter of 2024

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discus.

Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

CPRX or STVN: Which Is the Better Value Stock Right Now?

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, announced today the expansion of its Vertiva® platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva® easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-c.

Stevanato Group Will Introduce Its Large-Volume Vertiva® 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials and cartridges. The Alliance.

Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”

Sandoz Group AG

Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

SDZNY vs. STVN: Which Stock Is the Better Value Option?

Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript

Stevanato Group (STVN) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.15 per share a year ago.

Stevanato Group (STVN) Q2 Earnings Match Estimates

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared with the same period last year, and high-value solutions represented 40% of total reven.

Stevanato Group Reports Financial Results for the Second Quarter of 2024

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

STVN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Stevanato Group S.p.A. Shareholders Who Lost Money

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 6, 2024, to discuss f.

Stevanato Group to Report Second Quarter 2024 Financial Results on August 6, 2024

NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Levi & Korsinsky Reminds Shareholders of an Investigation into Stevanato Group S.p.A. (STVN) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Stevanato Group S.p.A. (STVN)

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Stevanato Group S.p.A. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - STVN

NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Levi & Korsinsky Reminds Stevanato Investors of the Ongoing Investigation into Potential Violations of Securities Laws - STVN

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

STVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Stevanato Group S.p.A.

NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

ATTENTION Stevanato Group S.p.A. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

News for Stevanato Group SpA Stock (STVN)